

J. B. CHEMICALS & PHARMACEUTICALS LIMITED

April 2, 2020

BSE Ltd. Phiroze Jeejebhoy Towers Dalal Street Mumbai 400 001

BSE Scrip Code: 506943

Stock Symbol: JBCHEPHARM

Dear Sir,

Sub: News about Ranitidine formulations in the US

We refer to the recent news item regarding USFDA's request for withdrawal of formulations of Ranitidine in the US market over higher level of NDMA found in some formulations in the market.

Following news over NMDA in September 2019, the Ranitidine API vendors of the Company have ensured that Ranitidine supplied by them meets the international guidelines related to the presence of NDMA and is well within the prescribed limits.

The Company continues to market Rantac[®], formulation of Ranitidine, in India. The Company has taken steps to ensure that the NDMA in the product is within the acceptable limits. The Company continues to evaluate the data obtained from the analysis of the product and results obtained have been satisfactory. Further, the Company has not yet launched this product in the US market.

We wish to add that Rantac[®] is being marketed by the Company in India for over 3 decades and so far no serious adverse event has ever been reported. As a responsible manufacturer, the Company continues to manufacture Rantac[®] that complies with all the standards set by the Drugs Controller General of India (DCGI). The Company shall continue to take all steps necessary for patient's safety and follow further guidance as and when provided by DCGI in this regard.

Kindly take the same on record.

Thanking you,

Yours faithfully, for J.B. Chemicals & Pharmaceuticals Limited

Sd/-

M. C. Mehta

Company Secretary and Vice President - Compliance